Previous 10 | Next 10 |
home / stock / gnftf / gnftf news
Madrigal Pharmaceuticals ( MDGL ) is a US biotech company that currently has only one drug, MGL-3196, under clinical investigation stage. Being Madrigal’s key asset, MGL-3196 has proven its strong potential in Non-Alcoholic Steatohepatitis ((NASH)) and is currently advancing to Phase ...
The broad market's down move notwithstanding, most companies working on NASH therapies have moved in lockstep with market following Conatus Pharmaceuticals' ( CNAT -56% ) failed Phase 3 study of emricasan. Many times investors perceive that one company's pain is another's gain. More ne...
Quick Take Genfit S.A. ( GNFT ) intends to raise $130 million in a global IPO from the sale of ADSs representing underlying ordinary shares, per an amended registration statement . The company is developing treatments for non-alcoholic steatohepatitis [NASH] conditions. GNFT expects Pha...
Loos, France-based Genfit S.A. ( OTCPK:GNFTF +2.6% ) has filed a preliminary prospectus for an initial public offering (IPO) of 5M American Depositary Shares (ADSs), applying for the ticker symbol "GNFT." More news on: Genfit SA, Healthcare stocks news, IPO News, Stocks on the move, ...
Nano cap Conatus Pharmaceuticals ( CNAT +22.2% ) is up on more than a 4x surge in volume. Shares have rallied 43% this week. More news on: Conatus Pharmaceuticals Inc., Madrigal Pharmaceuticals, Inc., Viking Therapeutics, Inc., Healthcare stocks news, Stocks on the move, ...
With one product candidate at phase 3 of development, Genfit (GNFTF) should interest institutional investors quite a bit. The results are expected by the end of 2019, which the market should remember well. Keep in mind that beneficial results could make the share price increase quite a bit. Ha...
Quick Take Genfit S.A. ( GNFT ) intends to raise $100 million in an IPO of ADSs representing ordinary shares, according to an F-1 registration statement . The firm is developing treatment candidates for non-alcoholic steatohepatitis [NASH] conditions. GNFT says it expects results from i...
Intercept's data in NASH fibrosis get a muted reception Intercept Pharmaceuticals ( ICPT ) last week announced data from its pivotal REGENERATE PhIII trial evaluating lead drug obeticholic acid ('OCA'), currently marketed as OCALIVA , in patients with liver fibrosis due to NASH. OCA has r...
Background NASH, or nonalcoholic steatohepatitis, has only been widely recognized as a disease for a short time. It may be more than one disease, given that it is defined as fatty, inflamed liver that is not due to alcohol abuse. Being a "not" condition implies that sub-types may exist. Ev...
Intercept Pharmaceuticals ( ICPT ) recently reported interim results from its phase 3 REGENERATE study. It noted that it had met on one co-primary endpoint, but failed on another. The company will be able to file for FDA and EMA approval, but a few issues associated with the drug may not a...
News, Short Squeeze, Breakout and More Instantly...
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the inclusi...
Ipsen’s Iqirvo ® (elafibranor) 80 mg tablets receives U.S. FDA accelerated approval as a first-in-class treatment for Primary Biliary Cholangitis (PBC) First-ever drug developed in-house by GENFIT to achieve U.S. FDA’s approval GENFIT is eligible to ...
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 29, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today detailed its presence ...